Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What changed???
Fingers crossed for an 8-K filing by end of next week, to reflect confirmation of the events mentioned in last weeks PR.
Didn't the press release from last week reaffirm your confidence? It was the most information regarding the traacquisition that has been shared since it was first announced last summer.
Perhaps it's moving in sympathy with this news? At the very least, this news shows that the tech (generally speaking, not specifically what VNTH has) is viable and that the NIH is interested in pursuing it.
https://www.rutgers.edu/news/rutgers-researchers-receive-nih-funding-develop-covid-19-breathalyzer-test
Rutgers Researchers Receive NIH Funding to Develop COVID-19 Breathalyzer Test
You expect .75 based on what news, confirmation that acquisition went through? If yes, then what price targets do you have in mind after the additional milestones are met:
1) Current with OTC filings
2) Announcement that PKG is developing a prototype for the Omentum Device
3) Announcement that clinical trials are expected later this year, or early next year
I assume this is the post you are referring to:
$CBBT An unbiased summary of my call with @CerebainBiotech addressing shareholder concerns.
— The Honky Stonk Man (@WILLFURU) April 21, 2021
Note: If you have any further questions please comment, a lot was discussed which I have not put in here as I wanted to keep it to 2 pages. pic.twitter.com/mIFfsJv0N6
COLLEGE STATION, TX / ACCESSWIRE / April 19, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company").
We continue to make great strides in the application of our multiple platforms for production of therapeutics for treating infectious diseases. Our future success will follow as we meet our goals to bring these therapeutics to market with new developments made possible by our extensive platform for producing new and effective therapies.
We acknowledge our partners Genscript (https://www.genscript.com), STC Biologics (https://stcbiologics.com) and California National Primate Research Center ( University of Southern California ) for their continued support in our research and development efforts. We are also grateful for the overwhelming support from world-renowned scientists and continue to expand our team of advisors to build a strong company based on research and development.
We are encouraged by the positive feedback received from pharmaceutical companies who have acknowledged an interest in partnering upon achievement of defined milestones. The milestones we have set include the following:
Monoclonal Antibodies for Treatment of HIV Milestones
1st Milestone: Testing of anti-HIV Monoclonal Antibodies at University of Montana
Status: in process. Time to completion: 1 month
2nd Milestone: Broad-based neutralization testing of existing anti-HIV Monoclonal Antibodies at University of Strasbourg, France
Status; in process. Time to completion: 2 months
3rd Milestone: Animal Studies of anti-HIV Monoclonal Antibodies at California National Primate Research Center , University of Southern California
Time to completion: 6 months following in vitro testing in process.
4th Milestone: Using Artificial Intelligence, identification of additional conserved immutable target sites (epitopes) on the HIV-1 virus
Status: Completed
5th Milestone: Production of additional Monoclonal Antibodies targeting identified sites (epitopes) on the HIV virus
Status: in process. Time to completion: 5-6 months
COVID-19
We are proud of the significant advances we have made in the development of Monoclonal Antibodies for treating Covid-19. We have reported that the Monoclonal Antibodies being produced by the Company will target immutable, conserved sites on SARS-CoV-2 (Coronavirus) that exist on the variant strains of the virus from the UK , Brazil , and South African.
These findings are considered highly significant in that the Center for Disease Control ("CDC") has reported these "variants of concern" are ones "for which there is evidence of an increase in transmissibility, more severe disease (meaning increased hospitalizations or deaths), a significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures."
Our AI platform developed in collaboration with Denver Scientific has been one of our many successes. The patentable discoveries will be significant in our ongoing partnering dialogue with pharmaceutical companies interested in treatments for the Coronavirus and numerous other infectious diseases.
We intent to expedite our development of anti-Coronavirus Monoclonal Antibodies including an eventual fast-track clinical trial to progress to market.
SARS-CoV-2 (Coronavirus) Monoclonal Antibodies Milestones
1st Milestone: Using Artificial Intelligence, identification of conserved immutable target sites (epitopes) on the Coronavirus
Status: Completed
2nd Milestone: Production of Monoclonal Antibodies targeting identified sites (epitopes) on the SARS-CoV-2 virus
Status: In process. Time to completion: 3-4 months
3rd Milestone: Fast-Track Clinical Studies
Time to Completion: 6 months following production of Monoclonal Antibodies
ITV-1 anti-HIV Therapeutics
Clinical trials are planned for the Company's patented anti-HIV therapeutics ITV-1. Earlier this year, we announced the execution of Articles of Association to form International Medical Partners ("IMPL"), a Bulgarian Limited Liability Company of which the Company is 50% owner. The Company's partners in IMBL will fund the total cost of the Clinical trials under the European Medicine Agency (the "EMA") standards and the application cost for the EMA permit for the Company's ITV-1 patented therapeutics for treating HIV. Under the Mutual Recognition Agreement (the "MRA") between the EMA and the United States Federal Drug Administration (the "FDA"), the Company believes that issuance of the EMA permit for the ITV-1 compound could qualify ENZC's treatment for recognition by the FDA. IMBL has entered negotiations to engage a CRO to begin the clinical trials required under EMA standards.
We will have a definitive timeline for the expected date of initiation and completion of clinical trials in the coming weeks.
Production of Monoclonal Antibodies for HTLV-1/2
We are committed to developing "universal, durable and broadly neutralizing" Monoclonal Antibodies for many infectious diseases. We have an "intent to partner" agreement with a pharmaceutical company to create Monoclonal Antibodies against HTLV-1/2. We expect to complete the production by the end of 2021.
Monoclonal Antibodies for HTLV-1/2
1st Milestone: Using Artificial Intelligence, identification of conserved immutable target sites (epitopes) on the HTLV1/2 virus
Time to Completion: 2-3 months
2nd Milestone: Creation of anti-HTLV1/2 Monoclonal Antibodies
Time to completion: 6-8 months following identification of target epitopes
CEO Charles Cotropia said, "The strength of our company lies in our multiple technology platforms and the ability to produce fully human Monoclonal Antibodies against conserved and immutable targets on identified viruses. The viruses that may be addressed using our technology range from HIV to the Coronavirus to HTLV-1/2 to Ebola and many more. These numerous targeted viruses and bacteria are listed on our website [http://enzolytics.com/proprietary-therapeutics/]. We will continue to provide updates on our developments and progress toward completing the milestones we have set. We thank all our shareholders for their ongoing support of our Company and its technologies."
About Enzolytics, Inc.
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases.
Enzolytics ' flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
About BioClonetics Immunotherapeutics, Inc.
BioClonetics Immunotherapeutics, Inc. , a wholly owned subsidiary of Enzolytics , is a Dallas and College Station, Texas biotech company with proprietary technology for producing fully human Monoclonal Antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for producing fully human Monoclonal Antibodies may be used to produce therapeutics treatments for many infectious diseases including the Coronavirus.
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC . ITV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.
While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to establish the efficacy of ITV-1 in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of ITV-1 in the United States , the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.
Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release, and the Company expressly disclaims any intention or obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.
IR Contact:
Enzolytics, Inc. 2000 North Central Expressway Plano, TX 75074
and
Research Center Enzolytics, Inc. Texas A&M University Institute for Preclinical Studies College Station, TX 77843-4478
SOURCE: Enzolytics, Inc.
View source version on accesswire.com: https://www.accesswire.com/641000/Enzolytics-Reports-Progress-On-Its-Multiple-Therapeutics-Platforms-and-Initiatives
Has anyone e-mailed or called Alan/Investor Relations recently?
Hoping for an update this week.
Also, try to read:
Corporate mergers and acquisitions can vary considerably in the time they take to be completed. This length of time may span from six months to several years.
Understood, but they both share a number of steps to reach completion.
This should provide some level of comfort:
How Long Does It Take for a Merger to Go Through?
https://www.investopedia.com/ask/answers/08/merger-completion-time.asp
Corporate mergers and acquisitions can vary considerably in the time they take to be completed. This length of time may span from six months to several years. There are a number of individual steps that need to be completed successfully by two public companies before they are legally combined into a single entity. Companies usually work with an investment bank to manage the merger process, which includes approvals, documentation, and implementation.
As companies go through the merger process, the merger timeline is often an important headline of communication. Executives will typically discuss merger details and field ongoing questions from analysts in quarterly earnings reports. Checkpoints, deadlines, and timelines can all be revised as the process is ongoing. Regulatory due diligence across the globe for worldwide conglomerates can turn up any number of idiosyncrasies that may lengthen the time to full approval.
My gut tells me that we're going into an extended dark period here, waiting for the next update. In Eric's last update on Twitter, he stated:
The company and its legal team are working as quickly as possible to address these issues. I will make further updates in the future to all shareholders when warranted and once again I thank you for your continued patience and support for the company.
That, combined with the fact that he had recently hired additional staff to help close the acquisition and bring filings current, indicate to me that they are hard at work on both matters, and that there really isn't anything else to update us on until both are complete.
My guess is that we're a month or two away from getting a significant update, or the confirmation of acquisition and filings being completed.
They're too legit, too legit to quit!
Eric will get 'er done.
I did see that on Twitter yesterday. It's seems as good a theory as any. Whatever the cause, the entire OTC market has been getting decimated for the last six weeks.
Short term future being the key words. Many of us are OK with that, and are focused on the mid to long term.
This makes sense. And to add to that, Former Apple Exec Brad Vroom - perhaps he convinced Cerebain to go the Apple route of in-house, vertical integration. Instead of outsourcing production for the Alzheimer's device, own the means of production, produce it yourself, and ensure quality control.
I read this earlier too. What makes you say it's huge news? Looks like one guy replaced another as President and CEO, with the former agreeing to continue as a consultant, primarily to assist RGBP with obtaining financing.
The bigger question is, where will the share price stabilize at pending the acquisition? If it's announced that the acquisition has been called off, then barring the announcement of another acquisition, this will tank back to trips, IMO.
I'm still up nicely, even at .04
Two weeks ago Eric stated that he's bringing additional auditors on board to speed up the completion of auditing financial statements. Assuming these additional auditors are also from NMS Consulting, they are likely already working on the project, with minimal ramp up time needed, since NMS has been working with Cerebain for several years now.
That is a plus, puts the wind at our backs.
On the downside, since the acquisition date has been pushed back numerous times, that raises the concern of some unforeseen complication in the financial records themselves, or perhaps a disagreement regarding acquisition terms, between Cerebain and NMS. Both of which could extend the timeline for completion by a fair amount.
Last, given that Eric is just now (two weeks ago) hiring additional auditors, I tend to believe that he is doing so primarily for optics - that is, to expedite the acquisition, since so many investors have been reaching out to Investor Relations with concerns.
Morning all.
Intimetec's location page on their website is gone:
https://www.intimetec.com/us/about-us/#locations
Perhaps they have left that site and PKG has full taken it over? Just speculating.
Financial filings, too.
BOOM indeed!
About time for an update!
Nope, just see the HQ site listed:
https://www.pkguis.com/contact
2145 E Pine Ave
Meridian, ID 83642
T: 800-730-5181
F: 208-577-5150
Email
General Inquiries
info@pkguis.com
Submit a Resume
hr@pkguis.com
Not sure. Is there a way to view historic/indexed versions of LinkedIn pages? I tried archive.org, no luck.
October 6th, 2020
Considering most of the OTC got kicked in the teeth today, not terrible.
I know that feeling all too well!
TAB87 - The info I posted earlier regarding NMS' consulting services can be found on their website:
https://nmsconsulting.com/nms-consulting-selected-as-strategic-advisor-to-cerebain-biotech-corp-for-acquisition-project/
NMS will provide management consulting services related to the formal due diligence of the PKG operations and financials, in addition to other analyses.
NMS Consulting, Inc. (“NMS”) is pleased to announce that it has been selected as strategic advisor by Cerebain Biotech Cop. (OTCPINK:CBBT) (“Cerebain”) for its planned acquisition of PKG, Inc. (“PKG”).
As part of the initial scope of services, NMS shall provide management consulting services related to the formal due diligence of the PKG operations and financials in addition to analysis related to revenue and cost synergies/savings, human capital and performance optimization, tax advisory, and mitigation strategy, risk management strategy, transaction and financing structuring to ensure optimal benefits to Cerebain and its shareholders. Additional services shall include post-merger integration, revenue growth strategies, market entry and expansion, digital transformation, cyber-security, and data privacy.
Trevor M. Saliba, Managing Partner and Global Head of Private Equity, M&A, and Strategy of NMS said, “We are very excited to continue working with Cerebain on this mandate. Having them as our client since 2018, we have had the privilege of working with them on various initiatives in preparation of their growth strategy. The acquisition of PKG begins the implementation of their long-term business plan.”
Irvine, California based Cerebain recently announced that it had executed a letter of intent to acquire all assets of PKG, an Idaho based leading contract manufacturing firm specializing in contract design, development, and manufacturing of system-level devices within the medical, aerospace, government, and industrial products sectors.
Eric Clemons, CEO of Cerebain said, “NMS Consulting has been invaluable in advising us on constructing our long-term corporate growth strategy. As we look to complete the PKG acquisition milestone, we are looking forward to continue working with the NMS Consulting team and their providing strategic counsel related to the integration of the PKG operations into Cerebain and moving to the next steps of growing Cerebain in accordance with our internal plan to maximize shareholder value.”
To learn more about Cerebain, please visit www.cerebain.com or connect with them on Twitter and Facebook.
yeah, I've had their Twitter page open in a browser window for the past five months, which I refresh every morning, in hopes of an update. Today is the first day that their tweets have been protected.
PKG's Twitter account is now protected. That is, you can no longer see their Tweets unless you follow the account on Twitter.
https://twitter.com/PKG_UIS
I think this could be an indicator of progress, as outlined below. Protecting one's tweets is part of data privacy 101. So it's possible that NMS is now at the point where they are guiding Cerebain and PKG through maturing their data security and privacy policies and practices. If that is the case, then that would likely indicate significant progress for the acquisition.
https://nmsconsulting.com/nms-consulting-selected-as-strategic-advisor-to-cerebain-biotech-corp-for-acquisition-project/
Additional services shall include post-merger integration, revenue growth strategies, market entry and expansion, digital transformation, cyber-security, and data privacy.
PKG has been updating their LinkedIn feed whenever Cerebain posts an update to their Facebook page:
https://www.linkedin.com/company/pkg-user-interface-solutions
To add to that, according to the SC 13G/A filing in January, EMA Group (which advises companies on turnarounds, M&A, and restructuring), increased their CBBT holdings from 15,000,000 shares a year earlier, to 70,000,000.
Proof? Evidence?
LMAO whatever. Yeah, Eric with an ear to ear grin, basking in a failed deal. Makes total sense!
Where is the weekly update?